Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
12.12. | TriSalus Life Sciences Direktor verkauft Aktien im Wert von 110.700 US-Dollar | - | Investing.com Deutsch | ||
10.12. | TLSI-Aktie erreicht 52-Wochen-Tief bei 3,5 US-Dollar | 1 | Investing.com Deutsch | ||
10.12. | TLSI stock touches 52-week low at $3.5 amid market challenges | 1 | Investing.com | ||
14.11. | TriSalus Reports Q3 2024 Financial Results and Provides Business Update | 98 | Business Wire | DENVER--(BUSINESS WIRE)--TriSalus Life Sciences Inc., (Nasdaq: TLSI), an oncology company integrating novel delivery technology with immunotherapy to transform treatment for patients with liver... ► Artikel lesen | |
14.11. | TriSalus Life Sciences, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
14.11. | TriSalus Life Sciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
13.11. | A Look Ahead: TriSalus Life Sciences' Earnings Forecast | 2 | Benzinga.com | ||
TRISALUS LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
01.11. | TriSalus Life Sciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
26.10. | TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Consensus Rating of "Buy" by Analysts | 2 | MarketBeat | ||
25.10. | Northland initiates TriSalus shares with outperform, cites sales growth | 3 | Investing.com | ||
25.10. | Northland stuft TriSalus-Aktien mit "Outperform" ein und verweist auf Umsatzwachstum | 1 | Investing.com Deutsch | ||
26.09. | TriSalus Life Sciences adds oncology expert to SAB | 1 | Investing.com | ||
26.09. | TriSalus Life Sciences erweitert wissenschaftlichen Beirat um Onkologie-Experten | 1 | Investing.com Deutsch | ||
23.09. | TriSalus reports breakthrough in liver tumor treatment | 2 | Investing.com | ||
16.09. | TriSalus vor Verdopplung? Oppenheimer prognostiziert starkes Kurswachstum | 2 | Investing.com Deutsch | ||
16.09. | Oppenheimer initiates TriSalus stock at outperform on liver cancer opportunity | - | Investing.com | ||
16.09. | Oppenheimer stuft TriSalus-Aktie mit "Outperform" ein aufgrund von Chancen in der Leberkrebs-Behandlung | 10 | Investing.com Deutsch | ||
13.09. | TriSalus Life Sciences CEO buys $75k in company stock | 1 | Investing.com | ||
13.09. | TriSalus Life Sciences CEO buys $24,850 in company stock | 1 | Investing.com | ||
10.09. | Trisalus Life Sciences director sells shares worth $49 | 1 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ASTRIA THERAPEUTICS | 9,560 | +1,16 % | Astria Therapeutics, Inc. - 8-K, Current Report | ||
ROCKET LAB USA | 23,900 | 0,00 % | Space Technology: Rocket Lab stellt zweites Raumfahrzeug für Varda Space Industries fertig | ||
BOIRON | 26,400 | -0,94 % | BOIRON: EVOLUTION OF GOVERNANCE | July 3rd, 2024
The Board of Directors of Laboratoires BOIRON, meeting today under the chairmanship of Thierry BOIRON, has enacted an evolution of the Group's governance.
In this context, Thierry... ► Artikel lesen | |
HARROW | 34,220 | -0,61 % | Harrow Health Aktie: Stabile Aussichten? | Der Aktienkurs des Augenheilkunde-Spezialisten Harrow Health verzeichnete am 07. Dezember einen bemerkenswerten Anstieg von 5,08 Prozent auf 39,32 USD. Die Entwicklung steht im Kontrast zum negativen... ► Artikel lesen | |
MEDICINOVA | 2,020 | 0,00 % | MediciNova, Inc.: MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND | LA JOLLA, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen | |
ESSA PHARMA | 1,610 | +0,31 % | ESSA Pharma Inc: ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024 | Company has initiated a process to explore and review strategic options focused on maximizing shareholder value
SOUTH SAN FRANCISCO, California and VANCOUVER... ► Artikel lesen | |
AQUESTIVE THERAPEUTICS | 3,650 | +0,27 % | Aquestive receives FDA Orphan Drug Exclusivity for Libervant | ||
REVIVA PHARMACEUTICALS | 1,335 | -11,00 % | Reviva announces pricing of $18M public offering of common stock and warrants | ||
LYRA THERAPEUTICS | 0,180 | +5,71 % | Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 Company reports topline safety results from ENLIGHTEN 1 Phase 3 extension... ► Artikel lesen | |
SHINECO | 2,240 | +10,89 % | Shineco, Inc.: Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement | BEIJING, June 27, 2024 (GLOBE NEWSWIRE) -- Shineco Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a producer of innovative diagnostic medical products and related medical devices, announced today... ► Artikel lesen | |
CUMBERLAND PHARMACEUTICALS | 2,280 | -1,72 % | Cumberland Pharmaceuticals Inc.: FDA Approves Acetadote sNDA | - New Dosing Regimen Simplifies Administration -
NASHVILLE, Tenn., Dec. 9, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty... ► Artikel lesen | |
CYANOTECH | 0,260 | 0,00 % | CYANOTECH CORP - 8-K, Current Report | ||
NUTRIBAND | 4,040 | -1,46 % | Nutriband Inc. Quarterly Report Highlights Record Revenue for Q3 up 50.94% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025 | ORLANDO, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today reported its financial results for the third quarter ended October 31, 2024. The Company reported... ► Artikel lesen | |
BAYER | 18,936 | +0,35 % | Bayer: Neues Medikament in der Pipeline | Die deutsche Chemie- und Pharmabranche kämpft weiterhin mit wirtschaftlichen Herausforderungen, doch Bayers neues Herzmedikament Acoramidis bietet einen Hoffnungsschimmer für 2025. Während die Branche... ► Artikel lesen | |
MERCK KGAA | 138,20 | -0,18 % | Merck Aktie: Sprung in neue Höhen! | Die Merck-Aktie verzeichnete am Handelstag einen deutlichen Rückgang und bewegte sich im XETRA-Handel auf 139,95 Euro abwärts. Dies entspricht einem Minus von 0,9 Prozent, wobei das Tagestief bei 139... ► Artikel lesen |